Prions Testing Market: TSE Diagnostics, Misfolded Protein Detection & Clinical Surveillance
公開 2026/04/01 16:17
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Prions Testings - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". In clinical neurology and veterinary public health, detecting transmissible spongiform encephalopathies (TSEs) presents a unique diagnostic challenge. Unlike conventional infectious agents, prions lack nucleic acids and rely on misfolded protein detection, requiring specialized assays capable of identifying pathological isoforms (PrP<sup>Sc</sup>) with high sensitivity. This report quantifies the market trajectory of prions testing—laboratory methods addressing these complexities through immunoassays and emerging amplification platforms.
The global market for Prions Testings was estimated to be worth US$ 1,712 million in 2025 and is projected to reach US$ 2,531 million, growing at a CAGR of 5.8% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097680/prions-testings
Defining the Technology: Detection of Misfolded Prion Proteins
Prions testing refers to laboratory methods designed to detect the presence, activity, or misfolding of prion proteins (PrP<sup>Sc</sup>), the infectious agents responsible for transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt–Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep, and chronic wasting disease (CWD) in deer and elk. These assays are critical for clinical diagnosis, post-mortem confirmation, and surveillance programs monitoring TSE transmission across human and animal populations.
Market Segmentation: Immunoassays, Molecular Biology, and Emerging Platforms
The market is segmented into immunoassays, molecular biology techniques, and others. Immunoassays—including ELISA and Western blotting—represent the largest revenue segment, serving as the established standard for post-mortem diagnosis and regulatory surveillance programs.
Molecular biology techniques—including real-time quaking-induced conversion (RT-QuIC)—represent the fastest-growing segment. RT-QuIC has emerged as the preferred method for ante-mortem CJD diagnosis, demonstrating superior sensitivity in cerebrospinal fluid samples compared to traditional immunoassays, enabling earlier and more accurate diagnosis.
Application Landscape: Clinical Neurology, Laboratory Diagnosis, and Research
The market serves three primary domains. Clinical neurology represents the fastest-growing segment, driven by RT-QuIC adoption. Recent CDC and ECDC guidelines have incorporated RT-QuIC as a diagnostic criterion for probable CJD, accelerating clinical adoption.
Laboratory diagnosis—including post-mortem confirmation and blood/tissue screening—represents the largest revenue segment, driven by regulatory surveillance programs for BSE, scrapie, and CWD requiring high-throughput immunoassay platforms. Research applications encompass basic prion biology and drug discovery, with increased activity following advances in understanding prion-like propagation in neurodegenerative diseases.
Competitive Landscape: Specialized Diagnostics and Global Leaders
The competitive landscape features specialized prion diagnostics companies and global life science tools providers. Bio-Rad dominates regulatory surveillance with established immunoassay platforms for BSE and CWD testing. Prionics AG and Roboscreen GmbH command substantial share in European veterinary surveillance. Eurofins, Abbott, and Roche participate through broader diagnostic portfolios, with Roche's RT-QuIC platform gaining traction in clinical neurology.
Industry Deep-Dive: CWD Surveillance and Clinical Adoption Drivers
Over the past six months, the industry has witnessed accelerated activity driven by two factors. First, geographic expansion of chronic wasting disease (CWD) in North America has intensified surveillance requirements. As of Q4 2025, CWD has been detected in 34 U.S. states, with prevalence exceeding 30% in some regions. State wildlife agencies have expanded testing programs, driving demand for high-throughput immunoassay platforms.
A recent case study from the Wisconsin Department of Natural Resources revealed that automated ELISA platforms reduced sample processing time by 58% while maintaining diagnostic sensitivity above 99.5%, enabling expanded surveillance coverage.
Second, clinical adoption of RT-QuIC for CJD diagnosis has accelerated following large-scale validation studies. A 2025 meta-analysis of 2,847 patients demonstrated RT-QuIC sensitivity of 92% and specificity of 99% for sporadic CJD, significantly outperforming traditional markers and driving adoption across academic medical centers.
Exclusive Insight: Divergence Between Surveillance and Clinical Diagnostic Segments
A distinct adoption pattern emerges across application segments. Regulatory surveillance programs—including BSE monitoring and CWD management—operate as centralized, government-funded systems emphasizing cost-per-test efficiency. Providers must demonstrate validated platforms with regulatory approvals and high-throughput capacity.
In contrast, clinical diagnostic applications operate through decentralized, hospital-based models emphasizing clinical sensitivity and integration with neurological workups. Providers must demonstrate strong clinical evidence and regulatory clearances (FDA, CE-IVD). This divergence requires distinct strategies: cost efficiency for surveillance; clinical validation and specialty channels for diagnostics.
Technical Barriers and Innovation Frontiers
Distinguishing variant CJD from sporadic CJD remains challenging, with implications for blood safety. Researchers are developing discriminatory assays targeting strain-specific conformations.
Another frontier is blood-based prion detection. Current ante-mortem diagnosis requires CSF sampling, limiting screening applications. Novel amplification platforms are under development for blood-based variant CJD screening, with early-stage studies showing promise.
Future Outlook: Sustained Growth Through Surveillance Expansion
Looking toward 2032, the market is poised for sustained growth at a 5.8% CAGR, reaching US$2.5 billion. Key catalysts include continued CWD geographic expansion, increasing RT-QuIC adoption for CJD diagnosis, and potential emergence of blood-based screening platforms. Providers delivering validated platforms with regulatory approvals across multiple jurisdictions will capture disproportionate market share.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
The global market for Prions Testings was estimated to be worth US$ 1,712 million in 2025 and is projected to reach US$ 2,531 million, growing at a CAGR of 5.8% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097680/prions-testings
Defining the Technology: Detection of Misfolded Prion Proteins
Prions testing refers to laboratory methods designed to detect the presence, activity, or misfolding of prion proteins (PrP<sup>Sc</sup>), the infectious agents responsible for transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt–Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep, and chronic wasting disease (CWD) in deer and elk. These assays are critical for clinical diagnosis, post-mortem confirmation, and surveillance programs monitoring TSE transmission across human and animal populations.
Market Segmentation: Immunoassays, Molecular Biology, and Emerging Platforms
The market is segmented into immunoassays, molecular biology techniques, and others. Immunoassays—including ELISA and Western blotting—represent the largest revenue segment, serving as the established standard for post-mortem diagnosis and regulatory surveillance programs.
Molecular biology techniques—including real-time quaking-induced conversion (RT-QuIC)—represent the fastest-growing segment. RT-QuIC has emerged as the preferred method for ante-mortem CJD diagnosis, demonstrating superior sensitivity in cerebrospinal fluid samples compared to traditional immunoassays, enabling earlier and more accurate diagnosis.
Application Landscape: Clinical Neurology, Laboratory Diagnosis, and Research
The market serves three primary domains. Clinical neurology represents the fastest-growing segment, driven by RT-QuIC adoption. Recent CDC and ECDC guidelines have incorporated RT-QuIC as a diagnostic criterion for probable CJD, accelerating clinical adoption.
Laboratory diagnosis—including post-mortem confirmation and blood/tissue screening—represents the largest revenue segment, driven by regulatory surveillance programs for BSE, scrapie, and CWD requiring high-throughput immunoassay platforms. Research applications encompass basic prion biology and drug discovery, with increased activity following advances in understanding prion-like propagation in neurodegenerative diseases.
Competitive Landscape: Specialized Diagnostics and Global Leaders
The competitive landscape features specialized prion diagnostics companies and global life science tools providers. Bio-Rad dominates regulatory surveillance with established immunoassay platforms for BSE and CWD testing. Prionics AG and Roboscreen GmbH command substantial share in European veterinary surveillance. Eurofins, Abbott, and Roche participate through broader diagnostic portfolios, with Roche's RT-QuIC platform gaining traction in clinical neurology.
Industry Deep-Dive: CWD Surveillance and Clinical Adoption Drivers
Over the past six months, the industry has witnessed accelerated activity driven by two factors. First, geographic expansion of chronic wasting disease (CWD) in North America has intensified surveillance requirements. As of Q4 2025, CWD has been detected in 34 U.S. states, with prevalence exceeding 30% in some regions. State wildlife agencies have expanded testing programs, driving demand for high-throughput immunoassay platforms.
A recent case study from the Wisconsin Department of Natural Resources revealed that automated ELISA platforms reduced sample processing time by 58% while maintaining diagnostic sensitivity above 99.5%, enabling expanded surveillance coverage.
Second, clinical adoption of RT-QuIC for CJD diagnosis has accelerated following large-scale validation studies. A 2025 meta-analysis of 2,847 patients demonstrated RT-QuIC sensitivity of 92% and specificity of 99% for sporadic CJD, significantly outperforming traditional markers and driving adoption across academic medical centers.
Exclusive Insight: Divergence Between Surveillance and Clinical Diagnostic Segments
A distinct adoption pattern emerges across application segments. Regulatory surveillance programs—including BSE monitoring and CWD management—operate as centralized, government-funded systems emphasizing cost-per-test efficiency. Providers must demonstrate validated platforms with regulatory approvals and high-throughput capacity.
In contrast, clinical diagnostic applications operate through decentralized, hospital-based models emphasizing clinical sensitivity and integration with neurological workups. Providers must demonstrate strong clinical evidence and regulatory clearances (FDA, CE-IVD). This divergence requires distinct strategies: cost efficiency for surveillance; clinical validation and specialty channels for diagnostics.
Technical Barriers and Innovation Frontiers
Distinguishing variant CJD from sporadic CJD remains challenging, with implications for blood safety. Researchers are developing discriminatory assays targeting strain-specific conformations.
Another frontier is blood-based prion detection. Current ante-mortem diagnosis requires CSF sampling, limiting screening applications. Novel amplification platforms are under development for blood-based variant CJD screening, with early-stage studies showing promise.
Future Outlook: Sustained Growth Through Surveillance Expansion
Looking toward 2032, the market is poised for sustained growth at a 5.8% CAGR, reaching US$2.5 billion. Key catalysts include continued CWD geographic expansion, increasing RT-QuIC adoption for CJD diagnosis, and potential emergence of blood-based screening platforms. Providers delivering validated platforms with regulatory approvals across multiple jurisdictions will capture disproportionate market share.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ